Loading organizations...
§ Private Profile · San Diego, CA, USA
Clinical-stage biopharma developing host-targeted recombinant protein therapies for viral respiratory infections by protecting host cells.
Based in San Diego, California, Ansun BioPharma is a clinical-stage biopharmaceutical company that develops host-directed recombinant protein therapeutics to treat severe viral respiratory infections. The organization focuses on biologic treatments, such as its lead candidate DAS181, which block viruses like influenza and parainfluenza from entering human respiratory cells rather than targeting the mutable viruses directly. Operating with approximately 25 employees, the pre-commercial enterprise has secured significant capital, including a $50 million National Institutes of Health contract, an $85 million Series A round in 2018, and an $80 million Series B financing in 2020. This clinical development is backed by prominent institutional investors such as Sinopharm Healthcare Fund, Lilly Asia Ventures, and Oceanpine Capital, alongside former chief executive officer Nancy Chang. Ansun BioPharma was originally founded in 2003 by virologists Dr. Mang Yu and Dr. Fang Fang.
Ansun BioPharma has raised $92.9M across 2 funding rounds.
Ansun BioPharma has raised $92.9M in total across 2 funding rounds.
Ansun BioPharma has raised $92.9M across 2 funding rounds. Most recently, it raised $7.9M Series B in October 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 15, 2019 | $7.9M Series B | Junson Capital, Korea Investment Partners, Oceanpine Capital | — | Announced |
| May 14, 2018 | $85M Series A | Lilly Asia Ventures, Sinopharm Capital | 3E Bioventures Capital, Joincap Investment, Lyfe Capital, Matrix Partners China, Oceanpine Capital, VI Ventures, YuanMing Capital | Announced |
Ansun BioPharma has raised $92.9M in total across 2 funding rounds.
Ansun BioPharma's investors include Junson Capital, Korea Investment Partners, Oceanpine Capital, Lilly Asia Ventures, Sinopharm Capital, 3E Bioventures Capital, Joincap Investment, LYFE Capital, Matrix Partners China, VI Ventures, YuanMing Capital.